Adeno-associated virus-mediated cancer gene therapy: current status
- PMID: 25444906
- PMCID: PMC4259838
- DOI: 10.1016/j.canlet.2014.10.045
Adeno-associated virus-mediated cancer gene therapy: current status
Abstract
Gene therapy is one of the frontiers of modern medicine. Adeno-associated virus (AAV)-mediated gene therapy is becoming a promising approach to treat a variety of diseases and cancers. AAV-mediated cancer gene therapies have rapidly advanced due to their superiority to other gene-carrying vectors, such as the lack of pathogenicity, the ability to transfect both dividing and non-dividing cells, low host immune response, and long-term expression. This article reviews and provides up to date knowledge on AAV-mediated cancer gene therapy.
Keywords: Adeno-associated virus; Cancer; Cancer gene therapy; Gene vehicle.
Published by Elsevier Ireland Ltd.
Conflict of interest statement
All authors declare that there are no conflicts of interest.
Figures
References
-
- Thomas RK. Overcoming drug resistance in ALK-rearranged lung cancer. The New England journal of medicine. 2014;370:1250–1251. - PubMed
-
- Su CH, Wu YJ, Wang HH, Yeh HI. Nonviral gene therapy targeting cardiovascular system. American journal of physiology. Heart and circulatory physiology. 2012;303:H629–H638. - PubMed
-
- Petrs-Silva H, Linden R. Advances in recombinant adeno-associated viral vectors for gene delivery. Current gene therapy. 2013;13:335–345. - PubMed
-
- Atchison RW, Casto BC, Hammon WM. Adenovirus-Associated Defective Virus Particles. Science. 1965;149:754–756. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
